Study on the characteristics of immune cell infiltration and its correlation with prognosis in patients with stage III B - IV lung adenocarcinoma by PET-CT based on the theory of 'protecting field' of traditional Chinese Medicine

Phase 1

Recruiting

• Conditions: ung cancer

• Registration Number: ITMCTR2000003886
• Lead Sponsor: Dongfang Hospital of Beijing University of Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Patients with lung adenocarcinoma confirmed by histopathology and / or cytology;
2. Patients who were classified as stage III B - IV according to the 7th edition of TNM staging system published by IASLC;
3. According to the NCCN guidelines for non-small cell lung cancer (NSCLC), the first-line treatment was carried out according to the recist1.1 evaluation standard for solid tumors;
4. Patients with at least one cold ablation lesion;
5. EGFR mutation (-), ALK rearrangement (-);
6. The patients who refused chemotherapy and radiotherapy in recent 1 month planned to receive systemic therapy (oral Chinese Medicine) + local treatment (target lesion biopsy + cold ablation);
7. ECOG PS <= 2
8. Patients whose expected survival time was more than 3 months;
9. Patients with TCM syndrome conforming to any of the five syndromes of lung cancer;
10. Patients who voluntarily participated in the study and signed informed consent.

Exclusion Criteria

1. Patients with multiple primary tumors;
2. Patients with other conditions not suitable for biopsy and cold ablation;
3. Patients with cold ablation lesions who have received other local minimally invasive treatment, such as radiotherapy, radiofrequency, seed implantation, etc.

Study & Design

• Study Type: Observational study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
lifetime;

Secondary Outcome Measures

Name	Time	Method
Tumour Markers;Peripheral immune cell;target focus;TCM syndrome;Positive rate of immune cells;Quality of Life evaluation;